Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Michael Leithead has maintained an Equal-Weight rating on Chemours (NYSE:CC) but lowered the price target from $40 to $31.
October 04, 2023 | 10:02 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Chemours but lowered the price target from $40 to $31.
The lowering of the price target by Barclays indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Chemours' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100